**Protein Engineering**:
- Techniques to modify the structure and function of proteins, including site-directed mutagenesis, directed evolution, and rational protein design
- Applications in developing improved therapeutic proteins with enhanced stability, activity, specificity, and pharmacokinetic properties
**Gene Engineering**:
- Genetic modification of cells and organisms, using tools like recombinant DNA technology, CRISPR/Cas9, and gene editing
- Enables production of therapeutic proteins, development of gene therapies, and genetic engineering of cell lines for research
**Analytics**:
- Analytical techniques to characterize and quantify biomolecules, including chromatography, mass spectrometry, spectroscopy, and electrophoresis
- Critical for process development, quality control, and lot release of biopharmaceuticals
**Immunogenicity**:
- Evaluation of the potential for therapeutic proteins and other biologics to induce unwanted immune responses in patients
- Important for assessing safety and efficacy during preclinical and clinical development
**AI and Computational Tools**:
- Leveraging artificial intelligence, machine learning, and in silico modeling for protein design, drug discovery, bioprocess optimization, and data analysis
- Accelerates various aspects of biopharmaceutical R&D
**CMC (Chemistry, Manufacturing, and Controls)**:
- Encompasses all aspects of the manufacturing process for biopharmaceuticals, including cell line development, upstream and downstream processing, formulation, and quality control
- Ensures consistent production of safe and effective drugs
**Biomarkers**:
- Measurable indicators of some biological state or condition, used to assess disease, guide treatment, and monitor therapeutic response
- Play a crucial role in the development and application of personalized medicine
**Tumor Microenvironment**:
- The complex cellular and molecular environment surrounding a solid tumor, including immune cells, blood vessels, and extracellular matrix
- Understanding the tumor microenvironment is key for developing immunotherapies and other targeted cancer treatments
**Biosimilars**:
- Biologic products that are highly similar to and have no clinically meaningful differences from an approved reference biologic
- Provide more affordable treatment options and increase patient access to important biologic medicines
Development 部分的几个重要组成部分
版主: Tlexander